GLP-1 Drug Prescriptions Rising in Teens with Diabetes, But Insurance Type Creates Gaps
GLP-1 receptor agonist dispensing increased among youth with type 2 diabetes from 2020-2023, but Medicaid-insured youth had significantly lower use compared to commercially insured youth.
Quick Facts
What This Study Found
GLP-1RA dispensing increased in youth with T2D from 2020-2023, but significant disparities existed between Medicaid and commercially insured youth.
Key Numbers
How They Did This
Multi-year cross-sectional study using Merative MarketScan Medicaid and Commercial databases; youth 10-17 with T2D; GLP-1 RA dispensing trends.
Why This Research Matters
Type 2 diabetes in youth is increasing rapidly, especially in disadvantaged populations. If Medicaid-insured kids can't access GLP-1 drugs, health disparities will widen at the youngest ages.
The Bigger Picture
This highlights how insurance coverage translates to treatment access in the most vulnerable population — children whose early diabetes management determines lifetime health outcomes.
What This Study Doesn't Tell Us
Claims data may not capture all prescriptions; dispensing doesn't confirm adherence; can't assess clinical outcomes; database may not represent all US youth.
Questions This Raises
- ?What specific barriers prevent Medicaid-insured youth from receiving GLP-1 drugs?
- ?Does the insurance-based access gap affect long-term diabetes outcomes in these children?
Trust & Context
- Key Stat:
- Insurance-based access gap Medicaid youth with T2D have lower GLP-1 RA dispensing than commercially insured peers
- Evidence Grade:
- Multi-year cross-sectional claims analysis — strong for trend identification and disparity documentation.
- Study Age:
- Published in 2026, documenting early trends in pediatric GLP-1 drug access.
- Original Title:
- GLP-1RA Dispensing in Youth With Type 2 Diabetes: 2020 to 2023.
- Published In:
- Pediatrics (2026)
- Authors:
- Chu, Patricia Y, Kelly, Andrea, Hennessy, Sean(2), Vajravelu, Mary Ellen, Huang, Jing, Amaral, Sandra
- Database ID:
- RPEP-15042
Evidence Hierarchy
Frequently Asked Questions
Can kids take GLP-1 drugs for diabetes?
Yes — some GLP-1 drugs are now approved for type 2 diabetes in youth aged 10 and older. However, this study shows that access depends heavily on insurance type, with Medicaid-covered children less likely to receive these newer treatments.
Why is the insurance gap concerning?
Youth with type 2 diabetes on Medicaid are often from disadvantaged communities with higher obesity rates. If they can't access the newest and most effective medications, existing health disparities will worsen during a critical period of development.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15042APA
Chu, Patricia Y; Kelly, Andrea; Hennessy, Sean; Vajravelu, Mary Ellen; Huang, Jing; Amaral, Sandra. (2026). GLP-1RA Dispensing in Youth With Type 2 Diabetes: 2020 to 2023.. Pediatrics. https://doi.org/10.1542/peds.2025-071971
MLA
Chu, Patricia Y, et al. "GLP-1RA Dispensing in Youth With Type 2 Diabetes: 2020 to 2023.." Pediatrics, 2026. https://doi.org/10.1542/peds.2025-071971
RethinkPeptides
RethinkPeptides Research Database. "GLP-1RA Dispensing in Youth With Type 2 Diabetes: 2020 to 20..." RPEP-15042. Retrieved from https://rethinkpeptides.com/research/chu-2026-glp1ra-dispensing-in-youth
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.